Harvard Medical School

Dr. Frank J. Veith Joins the Board of Directors of ViTAA Medical Solutions

Retrieved on: 
Thursday, February 29, 2024

ViTAA Medical Solutions, Inc., a leading innovator of precision vascular health designed to improve patient outcomes across the globe, is thrilled to announce the appointment of Frank J. Veith, M.D., a distinguished figure in the field of vascular surgery, to its Board of Directors.

Key Points: 
  • ViTAA Medical Solutions, Inc., a leading innovator of precision vascular health designed to improve patient outcomes across the globe, is thrilled to announce the appointment of Frank J. Veith, M.D., a distinguished figure in the field of vascular surgery, to its Board of Directors.
  • "We are honored to welcome Dr. Veith to our Board of Directors," said Mitchel Benovoy, CEO of ViTAA Medical Solutions.
  • Dr. Veith's addition to the Board underscores ViTAA's commitment to excellence and innovation in the development of medical technologies.
  • "I am honored and excited to join the ViTAA Board of Directors and contribute to their mission of transforming vascular care," said Dr. Veith.

Animal Biosciences Announces New Canine Clinical Research Evaluating Reversal of Age-Related Signs in Dogs

Retrieved on: 
Tuesday, March 5, 2024

Animal Biosciences, Inc. , a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.

Key Points: 
  • Animal Biosciences, Inc. , a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.
  • After five years of development and testing in dogs, leveraging discoveries made at Harvard Medical School, the study shows the first clinical evidence that it is possible to reverse age-related decline in dogs.
  • "The outcomes of the clinical trial, especially the enhancements in cognition, are encouraging and represent a unique achievement,” Dr. Olby noted.
  • In senior dogs, as in humans, this age-related decline can manifest as cognitive decline, increased frailty and lower engagement.

Tectonic Therapeutic Announces Participation at Investor Conferences in March

Retrieved on: 
Tuesday, February 27, 2024

Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March:

Key Points: 
  • Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March:
    The Tectonic management team will host one-on-one meetings during both conferences.
  • Interested investors should contact their TD Cowen and/or Leerink representative to schedule meetings.

Advancing Skin Cancer Detection: American Academy of Dermatology Journal Publishes DermaSensor's Breakthrough Melanoma Detection Results From A Major, Multicenter Trial

Retrieved on: 
Wednesday, February 28, 2024

In addition, the Negative Predictive Value (NPV) of 98.1% (95% CI, 91.8%-99.6%) indicates a high level of reliability for a negative device result of “Monitor”.

Key Points: 
  • In addition, the Negative Predictive Value (NPV) of 98.1% (95% CI, 91.8%-99.6%) indicates a high level of reliability for a negative device result of “Monitor”.
  • For a positive device result of “Investigate Further”, a 1-10 score is also provided to indicate the degree of similarity to malignant lesions.
  • The study found that the likelihood of melanoma for these positive results ranged from 10.3% for low scores (i.e., 1-3) to 47.4% for high scores (i.e., 8-10).
  • This automated, objective device can help in the fight against skin cancer, and the DermaSensor team is dedicated to making a meaningful contribution to its detection and prevention."

U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance

Retrieved on: 
Monday, February 26, 2024

HIV treatment resistance is permanent and irreversible, which can jeopardize future treatment options for PWH.

Key Points: 
  • HIV treatment resistance is permanent and irreversible, which can jeopardize future treatment options for PWH.
  • The M184V/I resistance mutation has been found to be present in a range (22-63%) of PWH with pre-existing resistance to nucleoside reverse transcriptase inhibitors (NRTIs) across various HIV subtypes.
  • “Clinical data have established Biktarvy as a long-term HIV treatment option for a broad range of PWH.
  • There were also zero cases of treatment-emergent resistance to Biktarvy, regardless of known or suspected pre-existing M184V/I resistance, in the final resistance analysis population.

Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease

Retrieved on: 
Monday, February 26, 2024

These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays.

Key Points: 
  • These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays.
  • This reach will provide greater access to patients for high-accuracy, non-invasive AD testing.
  • Traditional AD diagnosis has relied on combination of symptom presentation, brain imaging, and the detection of CSF biomarkers for AD.
  • “In our pursuit to build the global testing infrastructure for Alzheimer’s disease, Quanterix is pleased to work with several health systems whose combined networks treat millions of patients,” said Masoud Toloue, CEO of Quanterix.

BostonGene Bolsters Leadership Team to Accelerate Innovation and Growth

Retrieved on: 
Thursday, February 22, 2024

"On behalf of the BostonGene Board of Directors, I am thrilled to welcome Joe, Mark, and Ned to our team," said Andrew Feinberg, President and CEO of BostonGene.

Key Points: 
  • "On behalf of the BostonGene Board of Directors, I am thrilled to welcome Joe, Mark, and Ned to our team," said Andrew Feinberg, President and CEO of BostonGene.
  • Dr. Lennerz received an MD and a PhD in molecular medicine from the University of Erlangen, Germany.
  • "I am delighted to join BostonGene at such a pivotal moment in its trajectory.
  • In addition to BostonGene, Ned is a board member at RingCentral and Beyond Meat.

FastWave Earns Third Utility Patent for Next-Generation IVL Technology

Retrieved on: 
Wednesday, March 6, 2024

MINNEAPOLIS, March 6, 2024 /PRNewswire-PRWeb/ -- FastWave Medical, a clinical-stage medical device company developing differentiated intravascular lithotripsy (IVL) technology, announced the issuance of its third utility patent by the United States Patent and Trademark Office (USPTO). This latest patent – granted just three years from the company's inception – underscores FastWave's ambitious commitment to transforming the treatment of calcific artery disease.

Key Points: 
  • MINNEAPOLIS, March 6, 2024 /PRNewswire-PRWeb/ -- FastWave Medical, a clinical-stage medical device company developing differentiated intravascular lithotripsy (IVL) technology, announced the issuance of its third utility patent by the United States Patent and Trademark Office (USPTO).
  • "The issuance of FastWave's third utility patent is a testament to the phenomenal work being done by their experienced team.
  • By developing advanced lithotripsy platforms, FastWave aims to solve the gaps with existing IVL technology while improving ease of use and patient safety by reducing procedural complications.
  • Co-founder and CEO of FastWave Medical, Scott Nelson, emphasized the company's commitment to advancing IVL technology, stating, "We are thrilled to receive our third utility patent, which further validates the ingenuity of our IVL systems.

MelliCell Announces Dr. Fatima Cody Stanford as New Advisory Board Member

Retrieved on: 
Tuesday, February 27, 2024

This strategic move aligns with MelliCell's mission to revolutionize the treatment and understanding of metabolic diseases through advanced fat cell research.

Key Points: 
  • This strategic move aligns with MelliCell's mission to revolutionize the treatment and understanding of metabolic diseases through advanced fat cell research.
  • Dr. Stanford brings to MelliCell a rich legacy of expertise in obesity medicine as an Associate Professor of Medicine and Pediatrics at Massachusetts General Hospital (MGH) / Harvard Medical School (HMS).
  • As MelliCell prepares for its upcoming funding round, the addition of Dr. Stanford to the advisory board marks a pivotal moment in the company's trajectory towards establishing new standards in metabolic disease treatment.
  • "Joining MelliCell's dynamic team is an exciting opportunity to advance the fight against obesity through our focused research on adipose tissue," expressed Dr. Stanford.

J.P. Morgan Life Sciences Private Capital Team Adds Healthcare Veteran and Past Seagen CEO David Epstein to Advisory Board

Retrieved on: 
Tuesday, February 27, 2024

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.

Key Points: 
  • NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.
  • Mr. Epstein will now advise the J.P. Morgan Life Sciences Private Capital team.
  • The J.P. Morgan Life Sciences Private Capital team leverages JPMorgan Chase's scale, resources, data assets and healthcare expertise and sits within J.P. Morgan Private Capital, a venture and growth equity investment platform that is part of J.P. Morgan Asset Management.
  • The platform finances the continued growth of private companies and taps into significant pre-IPO value creation opportunities in the consumer and technology, and life sciences sectors.